PDCD1 and non-small cell lung carcinoma: Patients with melanoma and non-small cell lung cancer with low levels of PD-L1 expression had a response rate of only 10% when treated with PD-1 inhibitors, while patients with high PD-L1 expression had a response rate of 40–50% (25, 26).